Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis

American Journal of Kidney Diseases

Volumn 31, Issue 2, 1998, Pages 257-262

  Bro, Susanne ^a   Rasmussen, René A ^a   Handberg, Jens ^a   Olgaard, Klaus ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Calcium carbonate; Calcium ketoglutarate; Hemodialysis; Phosphate binder

Indexed keywords

2 OXOGLUTARIC ACID; ALFACALCIDOL; ALUMINUM GLYCINATE; CALCIUM CARBONATE; CALCIUM ION; CIMETIDINE; OMEPRAZOLE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG COST; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TABLET; TREATMENT OUTCOME; VOMITING;

EID: 0031906261     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v31.pm9469496     Document Type: Article

References (12)

1. Rodriguez M, Almaden Y, Hernandez A, Torres A: Effect of phosphate on the parathyroid gland: Direct and indirect? Curr Opin Nephrol Hypertens 5:321-328, 1996
2. Schaefer K: Unsatisfactory control of serum phosphate: Why is it so common and what can be done? Nephrol Dial Transplant 9:1366-1367, 1994.
3. Ritz E, Hergesell O: Oral phosphate binders without aluminum and calcium - A pipe dream? Nephrol Dial Transplant 11:766-768, 1996
4. Riedel E, Hampl H, Steudle V, Nündel M: Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations. Miner Electrolyte Metab 22:119-122, 1996
5. Zimmermann E, Wassmer S, Steudle V: Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism. Miner Electrolyte Metab 22:196-199, 1996
6. Gretz N, Zimmermann E, Sellger I, Hocker A, Laserre JJ, Strauch M: Kalziumverfügbarkeit und Phosphatbindungskapazität verschiedener Kalziumsalze. Klin Wochenschr 69:170, 1991 (suppl 23)
7. Schaefer K, von Herrath D, Asmus G, Umlauf E: The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia. Clin Nephrol 30:93-96, 1988
8. Lindenau K, Kokot F, Fröhling PT: Suppression of parathyroid hormone by therapy with a mixture of keto analogues/amino acids in hemodialysis patients. Nephron 43:84-86, 1986
9. Schaefer K, Erley CM, von Herrath D, Stein G: Calcium salts of ketoacids as a new treatment strategy for uremic hyperphosphatemia. Kidney Int 36:8136-8139, 1989 (suppl 27)
10. Arfeen S, Kirkwood A, Goodship THJ, Ward MK: Hypophosphatemic effect of 1% amino acid dialysis solution. Adv Perit Dial 5:167-170, 1989
11. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly(allylamine hydrochloride) (Rena-Gel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
12. Spengler K, Follmann H, Boos K-S, Seidel D, von der Haar F, Elsner R, Maywald F: Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Nephrol Dial Transplant 11:808-812, 1996